Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/24181
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDriessen, Johanna H. M.-
dc.contributor.authorde Vries, Frank-
dc.contributor.authorvan Onzenoort, Hein-
dc.contributor.authorHarvey, Nicholas C.-
dc.contributor.authorNeef, Cees-
dc.contributor.authorVAN DEN BERGH, Joop-
dc.contributor.authorVestergaard, Peter-
dc.contributor.authorHenry, Ronald M. A.-
dc.date.accessioned2017-08-09T10:24:07Z-
dc.date.available2017-08-09T10:24:07Z-
dc.date.issued2017-
dc.identifier.citationBRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 83(4), p. 923-926-
dc.identifier.issn0306-5251-
dc.identifier.urihttp://hdl.handle.net/1942/24181-
dc.description.abstractThe aim of the present study was to estimate the effect of incretins on fracture risk in the real-world situation by meta-analysis of the available population-based cohort data. Pubmed and Embase were searched for original articles investigating use of incretin agents, and fracture risk up to December 2015. Adjusted results were extracted and pooled by use of generic inverse variance methods, assuming a random-effects model. Neither current dipeptidyl peptidase 4-inhibitor use nor current glucagon-like peptide 1 receptor agonist use was associated with a decreased risk of fracture: pooled relative risk (pooled RR [95% confidence interval]: 1.02 [0.91-1.13] and 1.03 [0.87-1.22]), respectively. This meta-analysis demonstrated that current use of incretin agents, was not associated with decreased fracture risk. Our findings show the value of representative real-world populations, and the risks associated with suggesting benefits for medications on the basis of safety reporting in randomized controlled trials.-
dc.description.sponsorshipJ.D. and F.V. are employed by the Division of Pharmacoepidemiology & Clinical Pharmacology, which has received unrestricted funding from the Netherlands Organisation for Health Research and Development (ZonMW), the Dutch Health Care Insurance Board (CVZ), the Royal Dutch Pharmacists Association (KNMP), the private-public funded Top Institute Pharma (www.tipharma.nl), includes co-funding from universities, government, and industry), the EU Innovative Medicines Initiative (IMI), the EU 7th Framework Program (FP7), the Dutch Ministry of Health and industry (including GlaxoSmithKline, Pfizer, and others). J.B. reports grants from MSD, grants from Eli Lilly, grants from Amgen, grants from Will Pharma, outside the submitted work. N.H. reports grants, personal fees and other from Consultancy/lecture fees/honoraria, outside the submitted work. P.V. reports other from Eli Lilly, grants from MSD, other from Astra Zeica, outside the submitted work.-
dc.language.isoen-
dc.publisherWILEY-
dc.rights© 2016 The British Pharmacological Society-
dc.subject.otherdipeptidyl peptidase 4-inhibitors; fracture; glucagon-like peptide 1-receptor agonists; incretin agents; meta-analysis-
dc.subject.otherdipeptidyl peptidase 4-inhibitors; fracture; glucagon-like peptide 1-receptor agonists; incretin agents; meta-analysis-
dc.titleThe use of incretins and fractures - a meta-analysis on population-based real life data-
dc.typeJournal Contribution-
dc.identifier.epage926-
dc.identifier.issue4-
dc.identifier.spage923-
dc.identifier.volume83-
local.format.pages4-
local.bibliographicCitation.jcatA1-
dc.description.notes[Driessen, Johanna H. M.; de Vries, Frank] Utrecht Inst Pharmaceut Sci, Div Pharmacoepidemiol & Clin Pharmacol, Utrecht, Netherlands. [Driessen, Johanna H. M.; de Vries, Frank; Neef, Cees] Maastricht Univ, Care & Publ Hlth Res Inst CAPHRI, Med Ctr, Maastricht, Netherlands. [Driessen, Johanna H. M.; de Vries, Frank; van Onzenoort, Hein; Neef, Cees] Maastricht Univ, Dept Clin Pharm & Toxicol, Med Ctr, Maastricht, Netherlands. [de Vries, Frank; Harvey, Nicholas C.] Univ Southampton, MRC, Lifecourse Epidemiol Unit, Southampton, Hants, England. [van Onzenoort, Hein] Radboud Univ Nijmegen, Dept Pharm, Med Ctr, Nijmegen, Netherlands. [van den Bergh, Joop P. W.] Maastricht Univ, Dept Internal Med, Med Ctr, Maastricht, Netherlands. [van den Bergh, Joop P. W.] Univ Hasselt, Biomed Res Inst, Hasselt, Belgium. [Vestergaard, Peter] Aalborg Univ, Dept Clin Med, Aalborg, Denmark. [Vestergaard, Peter] Aalborg Univ Hosp, Dept Endocrinol, Aalborg, Denmark. [Henry, Ronald M. A.] Maastricht Univ, Dept Med, Med Ctr, Maastricht, Netherlands. [Henry, Ronald M. A.] Maastricht Univ, Cardiovasc Res Inst, Med Ctr, Maastricht, Netherlands.-
local.publisher.placeHOBOKEN-
local.type.refereedRefereed-
local.type.specifiedArticle-
dc.identifier.doi10.1111/bcp.13167-
dc.identifier.isi000397577800022-
item.validationecoom 2018-
item.fullcitationDriessen, Johanna H. M.; de Vries, Frank; van Onzenoort, Hein; Harvey, Nicholas C.; Neef, Cees; VAN DEN BERGH, Joop; Vestergaard, Peter & Henry, Ronald M. A. (2017) The use of incretins and fractures - a meta-analysis on population-based real life data. In: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 83(4), p. 923-926.-
item.contributorDriessen, Johanna H. M.-
item.contributorde Vries, Frank-
item.contributorvan Onzenoort, Hein-
item.contributorHarvey, Nicholas C.-
item.contributorNeef, Cees-
item.contributorVAN DEN BERGH, Joop-
item.contributorVestergaard, Peter-
item.contributorHenry, Ronald M. A.-
item.accessRightsRestricted Access-
item.fulltextWith Fulltext-
crisitem.journal.issn0306-5251-
crisitem.journal.eissn1365-2125-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
driessen 1.pdf
  Restricted Access		Published version213.75 kBAdobe PDFView/Open    Request a copy
Show simple item record

SCOPUSTM   
Citations

22
checked on Sep 5, 2020

WEB OF SCIENCETM
Citations

25
checked on May 8, 2024

Page view(s)

78
checked on Sep 7, 2022

Download(s)

60
checked on Sep 7, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.